Streetbeat News

ABCL

AbCellera Biologics Inc.

https://www.abcellera.com

Industry

Biotechnology

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Open

2.75

Mkt cap

783M

Volume

3.3M

High

2.76

P/E Ratio

-4.34

52-wk high

6.05

Low

2.57

Div yield

N/A

52-wk low

2.33

AbCellera Biologics reported Q1 2024 earnings with a GAAP EPS of $(0.14), surpassing the $(0.16) estimate. However, their sales of $9.954M fell short of the $10.836M estimate, marking an 18.36% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 8:13 pm

AbCellera (NASDAQ:ABCL) presented new data on its T-cell engager (TCE) programs at AACR 2024, showcasing advancements in cancer therapy. The data highlighted TCEs with potent tumor-cell killing and low cytokine release for targets like PSMA, B7-H4, and 5T4, and costimulatory CD28-binding antibodies enhancing T-cell activation without toxicity. Additionally, AbCellera is expanding TCE target space with high specificity for MAGE-A4-pMHC. These developments position AbCellera to advance TCEs as a drug class, potentially improving efficacy and safety for solid tumor treatments.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 4:06 pm

AbCellera and Biogen Inc. have announced a strategic collaboration to discover antibodies for a novel target that could enable the delivery of biotherapeutics to the brain, focusing on neurological conditions. AbCellera will receive an upfront payment and may also receive additional milestone payments and royalties on future net sales of products arising from this collaboration.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 1:03 pm

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:05 pm

AbCellera Biologics shares are trading lower following the announcement of mixed Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 3:52 pm

AbCellera Biologics (NASDAQ:ABCL) reported Q4 earnings with an EPS of $-0.17, missing estimates by 30.77% and showing a revenue decline of $12.37 million from the previous year. Despite beating EPS estimates in Q3 2023, this quarter's results could impact investor sentiment negatively.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:30 pm

AbCellera Biologics reported Q4 2023 earnings with a GAAP EPS of $(0.17), missing the $(0.13) estimate, but sales of $9.18M exceeded the $8.88M forecast. This represents a 57.40% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:26 pm

Earnings reports for various companies are scheduled for February 20, 2024, with a mix of projected earnings and losses across different sectors. Notable companies include Walmart, Home Depot, Medtronic, and Barclays, among others, with expectations ranging from significant profits to losses per share.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 11:52 am

Keybanc analyst Scott Schoenhaus has initiated coverage on AbCellera Biologics with an Overweight rating and set a price target of $6. The company is listed on NASDAQ under the ticker ABCL.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:03 am

AbCellera has presented new data from its T-cell engager platform at SITC 2023. The data shows that diverse CD3-binding antibodies can optimize T-cell engager function beyond what is possible by modifying a single CD3-binder.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.